Proposal to list anaesthesia small equipment and consumable devices supplied by Teleflex Medical New Zealand Ltd
PHARMAC is seeking feedback on a proposal to list a range of Anaesthesia Small Equipment and Consumable devices in Part III of Section H of the Pharmaceutical Schedule from 1 May 2018.
We propose to list a range of Anaesthesia Small Equipment and Consumable devices (“Anaesthesia Products”) supplied by:
- Teleflex Medical New Zealand Ltd (“Teleflex”)
What would the effect be?
For DHBs
From 1 May 2018, Teleflex ranges of Anaesthesia Products would fall under a proposed national agreement (“Agreement”) that all DHBs may purchase under. Listing on the Pharmaceutical Schedule would be conditional on the approval of PHARMAC’s Board or its delegate. This Agreement would not be for sole supply, with DHBs continuing to be able to purchase other suppliers’ brands of Anaesthesia Products.
This Agreement would supersede any existing DHB contracts with Teleflex for the devices listed in the Schedule One of the Agreement. Any device listed in a PHARMAC Agreement and purchased by a DHB would be at the Price, Terms and Conditions stated in the Agreement, effective from the date of listing on the Pharmaceutical Schedule.
PHARMAC estimates that the Teleflex Agreement would offer national savings to DHBs of $130,500 per annum, based on current usage.
Teleflex has some products that are new to DHBs and the Agreement would provide an increased range of Anaesthesia Products from which clinicians could choose.
As a part of the Agreement Teleflex would provide educational services that would be tailored to the individual needs of DHB hospitals, in formats and at times as required by DHB Hospitals.
Pricing for Anaesthesia Products, subject to any prior termination of the Agreements, would not be increased without prior consultation and approval by PHARMAC.
Who we think will be interested
- Suppliers and Wholesalers
- DHB Staff
- Clinical Engineers
- Anaesthetists
- Anaesthetic Technicians
- Clinical staff involved with airway management and emergency respiratory resuscitation
- Procurement Officers
About the anaesthesia products category
The scope of the Anaesthesia Products category was defined as:
- Airway visualisation devices and associated consumables
- Stand-alone depth of anaesthesia monitoring systems and associated consumables
- Consumable medical devices used for the purpose of:
- Acute airway management
- Anaesthesia gas delivery
Consumable medical devices included both single use items and defined-life multiple use items.
These devices are integral to the delivery of anaesthesia and are ubiquitous supplies in all DHB operating theatres. Some of these devices are also used for airway management and emergency respiratory resuscitation and as such may also be used by clinicians other than anaesthetists.
Why we’re proposing this
In March 2017 PHARMAC issued a Request for Proposals (RFP) for anaesthesia products. The RFP was for non-exclusive national agreements for listing on the Pharmaceutical Schedule.
PHARMAC has been working with suppliers to seek provisional agreements. This proposal is the latest to arise from the contracting process. We intend to consult on additional proposed agreements with other suppliers over the next few months.
Details about our proposal
PHARMAC has entered into a provisional agreement with Teleflex for a range of Anaesthesia Products.
This proposal would result in Pharmaceutical Schedule listings for 457 products.
The full list of products in the proposal is attached to this consultation. Pricing has been made available to appropriate DHB personnel.
To provide feedback
Send us an email: jacquie.pillay@pharmac.govt.nz by 5 pm on Wednesday 28 February 2018.
All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.
Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.
We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. PHARMAC will give due consideration to any such request.